Hinge Health (HNGE) CFO Budge James Sells $4.9M of Stock

Budge James, the Chief Financial Officer of Hinge Health, Inc. (NYSE: HNGE), sold 47,720 shares on October 12, 2026, for approximately $4.9 million at a price of $103.13 per share. This sale was part of a planned transaction.

Inside Budge James' Trade

James's sale represents a significant transaction, with shares traded at a price of $103.13. The total value of this sale was about $4,921,578.34. The stock's recent trading price shows a strong position, recently around $99.47.

Other Institutional Activity in Hinge Health

Several other institutional investors have recently adjusted their positions in Hinge Health. Blackrock Inc. increased its stake by 2,662,624 shares, bringing its total to 3,570,131 shares worth about $354 million. Vanguard Portfolio Management LLC added 735,375 shares, totaling 2,146,032 shares valued at approximately $212.8 million. Conversely, 11.2 Capital Management, LLC reduced its holdings by 1,239,923 shares, leaving it with 2,464,657 shares worth about $244.4 million.

Hinge Health, Inc. Stock Down 5.3%

Hinge Health's stock recently trades at $99.47, which is above its 50-day moving average of $92.61 and significantly above its 200-day average of $63.29. However, it is still about 7% below its 52-week high of $107. This positioning indicates that the stock is currently in a strong upward trend but remains below its recent peak.

Recent Earnings

Hinge Health reported trailing twelve-month revenue of $720.1 million, showcasing a year-over-year revenue growth of 53%. The company's earnings per share (EPS) stands at $3.03. The next earnings report is scheduled for November 2, 2026.

Insider Buying and Selling at Hinge Health, Inc.

Earlier this year, LLC Insight Holdings Group made several notable transactions involving Hinge Health shares. On June 29, 2026, they sold 1,466,667 shares as part of a planned sale at an average price of $82.84, valued at about $121.5 million. Prior to that, they had also made substantial purchases of Hinge Health shares on June 23 and June 25, 2026.

Analysts Set New Price Targets

On October 12, 2026, Barclays maintained an Overweight rating on Hinge Health, setting a price target of $110. This follows recent ratings from other firms, including Truist Securities, which maintained a Buy rating with a target of $112, and Needham, which also has a Buy rating with a target of $115. The consensus among analysts is positive, with a mean price target of $112.13 based on 16 opinions.

About Hinge Health

Hinge Health, Inc. focuses on improving healthcare delivery through technology. The company specializes in musculoskeletal system care, providing automated solutions for injury treatment and rehabilitation. Its services include AI-powered motion tracking and a proprietary nerve stimulation device, primarily aimed at self-insured employers.

Bottom Line

As Hinge Health approaches its next earnings date on November 2, 2026, investors will be watching closely for further updates on its performance. Budge James's recent sale adds to the ongoing trading activity surrounding the company's stock, which has shown strong growth but is currently trading below its mean price target.